A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.
A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.
The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.
The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.
People with type 1 diabetes treated with multiple daily insulin injections struggle to achieve guideline-recommended targets for time in hypoglycemia while simultaneously reaching their glycated hemoglobin goals, researchers report.
Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.
Engineer turned endocrinologist Rayhan Lal reflects on the shape of artificial pancreas research and what changes are needed to best benefit people with diabetes (18:54).
A novel insulin that can be given as a once-weekly injection has achieved promising results in a randomized phase 2 trial involving people with type 2 diabetes.
Engineer turned endocrinologist Rayhan Lal reflects on the shape of artificial pancreas research and what changes are needed to best benefit people with diabetes (18:54).
This content content collection includes details on:
A benefit/risk tool to inform prescribing decisions for SGLT2 inhibitors
The patient experience of diagnosis and self-management with SGLT2 inhibitors
Translating SGLT2 inhibitor cardiovascular evidence into practice
Key evidence and implications for clinical practice
This collection was made possible by educational funding provided by Napp Pharmaceuticals Ltd.
The continuing evolution of GLP-1RAs
Chaired by John Wilding, with Julie Lovshin and Kamlesh Khunti, this webcast discusses the current and future treatment landscapes for type 2 diabetes focusing on once-weekly and next generation glucagon-like peptide‑1 receptor agonists.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
